Therma Bright Provides Corporate Update on Pain Relief Device Incorporating Medicinal Cannabis, Further Testing of TherOZap(TM) Technology Against the Zika Virus and Finalizes Multi-Use ActivatorsToronto, Ontario--(Newsfile Corp. - October 1, 2018) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, provides the following updates:
Therma Bright Advances Design of Pain Relief Device Incorporating Medicinal Cannabis, CBD from Hemp and other Pain Relief formulations:
Further to its press release on May 8th, 2018 Therma Bright is pleased to announce that after extensive consultation with designers and engineers the Company has created its first design for its pain relief device. The pain relief device will incorporate the Company's thermal therapy technology along with new technology and pain relief formulations in the form of creams, gels or salves. The Company intends to conduct research of its pain relief technology with medicinal cannabis, CBD from hemp and other pain formulations. Therma Bright has identified multiple pain relief clinics and clinical research groups that can test Therma's pain relief technology. Therma has initiated patent and trademark protection for its pain relief technology for the relief of general or chronic pain which main include; back pain, arthritic pain and other orthopedic pain utilizing its thermal therapy technology and medicinal cannabis, CBD from hemp and other pain formulations. All research and handling of any medicinal cannabis will be dealt with through authorized and licensed research facilities. Therma expects to finalize a prototype and various pain relief formulations, working with Therma's advisors, to test with the pain relief prototype in the near future.
Therma Bright short-lists testing laboratories for further testing of TherOZap™ technology against the Zika virus and makes TherOZap™ product improvements:
Therma Bright announces that further to its press release on January 8, 2018 outlining results indicating effectiveness of its TherOZap™ technology at inhibiting the Zika virus, and its press release on April 19th indicating the Company will continue testing of the TherOZap™ technology against the Zika virus, that the Company has short listed research laboratories to further test the TherOZap™ against the Zika virus. Based on feedback received during its last round of tests, the Company has made several improvements to the TherOZap™ technology prototype that will be easier to use to conduct testing by research laboratories. Once testing is initiated the Company expects testing to last several months. The Company will follow up with additional testing, providing efficacy of the TherOZap™ technology during the initial tests against the Zika virus, with further in-vitro testing of the Zika virus or other mosquito borne diseases to be followed up by in-vivo testing if warranted. Therma Bright hopes to prove that the TherOZap™ technology will be effective as a second line of defense after being bitten by a mosquito against the Zika virus. Once the TherOZap™ technology proves effective, the Company expects to extend the prototype improvements to Therma's final commercial device with an aim to market any claims on marketing material with appropriate regulatory approval.
Therma Bright Completes Multi-Use Activator Design for InterceptCS™ and Reviewing Manufacturing Alternatives in North America and Asia.
Therma Bright is pleased to report that it has completed the final design for a multi-use treatment activator for its InterceptCS™ product, the Company's thermal therapy device approved in Canada as a Class II medical device with the claim, "For the prevention and relief of the symptoms of herpes labialis (cold sores)." The InterceptCS™ system is a thermal therapy technology that uses timed, measured heat applications to prevent a cold sore. The technology has advantages for cold sore sufferers as there is no messy creams to apply or expensive, potentially harmful drugs to ingest to treat a cold sore.
The legacy InterceptCS™ treatment activator is good for one use and is then discarded. Therma Bright has now designed a new multi-use treatment activator housed in the same plug and play treatment activator used today. It is anticipated the Company will sell 5,10 or 20, multi-use treatment activations which offer enhanced value to consumers on a per unit basis. The Company now plans to market the multi-use treatment activators, and existing InterceptCS™ inventory, through an extensive social media marketing campaign through its soon to be launched e-commerce website - www.coldsores.com The multi-use treatment activator is meant to support the existing InterceptCS™ product and will represent a high margin recurring revenue stream for the Company. Therma Bright is consulting with designers and engineers to develop a new cold sore treatment system using advanced technology which may include artificial intelligence "AI" and Internet of Things "IoT" among other technological improvements.
Currently, Therma Bright has over 15,000 InterceptCS™ systems in inventory which have been written down on the Company's balance sheet. The current inventory is fully functional and when sold will benefit Therma's bottom line. The InterceptCS™ system retails for $49.99 online and includes two treatment activators. The legacy single use treatment activator retails for $14.99 on a per unit basis. The multi-use activator will sell for $9.99 or less on a per unit basis to prevent a cold sore outbreak providing enhanced value to the consumer. The InterceptCS™ product is currently sold online and at www.interceptcs.com or www.interceptcoldsore.com Both websites will be replaced by the Company's new e-commerce website in the near future: www.coldsores.com.
Therma Bright is pleased to announce the launch of its corporate website:
Rob Fia, CEO commented:
"Therma Bright would like to thank its shareholders for being patient as the Company worked with its management, advisors, designers and engineers over the last few quarters to accomplish the latest progress at Therma Bright. We expect to report more news on the application of its technology with advanced technology and exciting new applications and sectors for its technology."
About Therma Bright Inc.:
Therma Bright is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs. Clear and healthy skin for all is at the core of the Company's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The Company's breakthrough proprietary technology delivers effective, non-invasive and pain free skin care.
Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). The Company received approval for the above claims from FDA (United States) in 1997.
For further information please contact:
Therma Bright Inc.
FORWARD LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events or the Company's future performance and include development of the Company's pain relief device, further testing of the TherOZap™ device against the Zika virus and manufacture of multi-use activators for its InterceptCS™ product, all as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. In addition to other risks, the Company may not complete all or any of the transactions as described in this news on the timelines described. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES